Gastritis - Pipeline Review, H1 2018

  • ID: 4531944
  • Drug Pipelines
  • 53 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • BCWorld Pharm Co Ltd
  • Daewon Pharm Co Ltd
  • Recce Ltd
  • RedHill Biopharma Ltd
  • Sequella Inc
  • MORE
Gastritis - Pipeline Review, H1 2018

Summary:

This latest Pharmaceutical and Healthcare disease pipeline guide Gastritis - Pipeline Review, H1 2018, provides an overview of the Gastritis (Gastrointestinal) pipeline landscape.

Gastritis is characterized by inflammation or swelling of the lining of the stomach. Acute gastritis lasts for a short period of time while chronic gastritis lasts for a long period of time (months to years). Gastritis can be caused by medications such as ibuprofen, aspirin, naproxen on long periods of consumption, excess intake of alcohol, Helicobacter pylori infection, certain autoimmune disorders, bile reflux, substance abuse (cocaine), consumption of corrosive or caustic substances such as poisons, extreme stress, viral infections and trauma. The symptoms of gastritis may include loss of appetite, nausea and vomiting, abdominal pain and black stools. Treatment includes use of antacids, Histamine 2 (H2) antagonists and proton pump inhibitors.

Report Highlights:

This latest pipeline guide Gastritis - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Gastritis (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Gastritis (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Gastritis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 4, 2 and 2 respectively.

Gastritis (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Gastritis (Gastrointestinal).
  • The pipeline guide reviews pipeline therapeutics for Gastritis (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Gastritis (Gastrointestinal) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Gastritis (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Gastritis (Gastrointestinal)
Reasons for Purchase:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Gastritis (Gastrointestinal).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Gastritis (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • BCWorld Pharm Co Ltd
  • Daewon Pharm Co Ltd
  • Recce Ltd
  • RedHill Biopharma Ltd
  • Sequella Inc
  • MORE
Introduction

Report Coverage

Gastritis - Overview

Gastritis - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Gastritis - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Gastritis - Companies Involved in Therapeutics Development

BCWorld Pharm Co Ltd

Daewon Pharm Co Ltd

Daewoong Pharmaceutical Co Ltd

Recce Ltd

RedHill Biopharma Ltd

Sequella Inc

Gastritis - Drug Profiles

AK-002 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BCWPA-001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DW-3101 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DWJ-1366 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HPi-1 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

netazepide - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ondansetron hydrochloride CR - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RECCE-327 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SQ-109 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gastritis - Dormant Projects

Gastritis - Product Development Milestones

Featured News & Press Releases

Jun 19, 2017: RedHill Biopharma to Host Conference Call on Successful Phase III Top-Line Results with BEKINDA for Acute Gastroenteritis

Feb 13, 2017: RedHill Biopharma Announces Enrollment of Last Patient in BEKINDA Phase III Study for Acute Gastroenteritis

Nov 03, 2016: RedHill Biopharma Provides Update on Ongoing Phase III and Phase II studies with BEKINDA and Expected Timing of Top-Line Results

Mar 02, 2015: Positive Bioavailability Studies of RedHill's BEKINDA to be Presented at the 2015 American Society for Clinical Pharmacology and Therapeutics Meeting

Dec 17, 2014: RedHill Biopharma Announces First Patients Enrolled in the Phase III Study of RHB-102 (BEKINDA) for Gastroenteritis and Gastritis

Dec 09, 2014: RedHill Biopharma Submits BEKINDA (RHB-102) European Marketing Authorization Application for Oncology Support

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Gastritis, H1 2018

Number of Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Gastritis - Pipeline by BCWorld Pharm Co Ltd, H1 2018

Gastritis - Pipeline by Daewon Pharm Co Ltd, H1 2018

Gastritis - Pipeline by Daewoong Pharmaceutical Co Ltd, H1 2018

Gastritis - Pipeline by Recce Ltd, H1 2018

Gastritis - Pipeline by RedHill Biopharma Ltd, H1 2018

Gastritis - Pipeline by Sequella Inc, H1 2018

Gastritis - Dormant Projects, H1 2018

List of Figures

Number of Products under Development for Gastritis, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products by Targets, H1 2018

Number of Products by Stage and Targets, H1 2018

Number of Products by Mechanism of Actions, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Molecule Types, H1 2018

Number of Products by Stage and Molecule Types, H1 2018
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • BCWorld Pharm Co Ltd
  • Daewon Pharm Co Ltd
  • Daewoong Pharmaceutical Co Ltd
  • Recce Ltd
  • RedHill Biopharma Ltd
  • Sequella Inc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll